Alzheimer's disease
Conditions
Interventions
Gold Standard:Comprehensive cognitive assessment in conjunction with brain imaging (structural changes in MRI cephalic horizontal and sagittal visualization) was used for the diagnosis.
Index test:Methods: Single molecule immunoassay
Biomarkers: blood-based exosomes
equipment:Quanterix HD-1/HD-X
Sponsors
Xi'an Area Medical Laboratory Center
Eligibility
Sex/Gender
All
Age
55 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) 55= age =85 years, male or female; (2) The subjects themselves and their families voluntarily participate and are capable of completing the cognitive function questionnaire and venous blood collection as stipulated in the program; (3) AD cases are patients diagnosed by trained psychiatrists in charge or above. Diagnosis was made using the National Institute of Aging (NIA) and the Alzheimer's Association (AA), the new diagnostic Guidelines for AD (NIA-AA diagnostic criteria). Meeting the NIA-AA diagnostic criteria is likely to be the core clinical diagnostic criteria for AD (probable AD) or AD (possible AD). Gender, education level is not limited. (4) The condition is stable and the consciousness is clear.
Exclusion criteria
Exclusion criteria: (1) Head magnetic resonance examination found the following conditions: MRI showed significant focal lesions, white matter lesion rating scale = level 2; There were more than 2 lacunar infarcts with a diameter greater than 2cm, and there were luminal infarcts in key areas such as thalamus, hippocampus, entorhinal cortex, parorhinal cortex, cortex and other subcortical gray matter nuclei. (2) Have suffered from neurological diseases (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy, etc.); (3) Subjects with unstable or severe heart, lung, liver, kidney, hematopoietic system diseases (including unstable angina pectoris, uncontrolled asthma, active gastric bleeding, cancer, etc.); (4) Subjects with autoimmune diseases; (5) Participants with visual and hearing disorders who could not complete neuropsychological tests and scales; (6) Subjects who abused alcohol or drugs; (7) Persons with mental illness, including persons with severe depression; (8) For any reason, the researcher believes that it is impossible to complete the subjects tested in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Aß42;Total Tau protein in plasma;Plasma P-181-Tau;Plasma C3;Plasma LCN2;Plasma exosome Aß42;Total Tau protein in plasma exosomes;Plasma exosome P-181-Tau;Plasma exosome C3;Plasma exosome LCN2;Cognitive ability;MRI brain imaging; | — |
Countries
China
Contacts
Public ContactZeng Xianfei
Xi'an Area Medical Laboratory Center
Outcome results
None listed